Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Gross Margin (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Gross Margin for 8 consecutive years, with 85.84% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 373.0% to 85.84% in Q4 2025 year-over-year; TTM through Dec 2025 was 83.8%, a 245.0% decrease, with the full-year FY2025 number at 83.8%, down 245.0% from a year prior.
  • Gross Margin was 85.84% for Q4 2025 at Ultragenyx Pharmaceutical, up from 82.5% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 96.39% in Q2 2021 to a low of 79.42% in Q1 2025.
  • A 5-year average of 89.32% and a median of 90.03% in 2022 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: surged 443bps in 2021, then plummeted -565bps in 2022.
  • Ultragenyx Pharmaceutical's Gross Margin stood at 95.79% in 2021, then dropped by -1bps to 94.85% in 2022, then dropped by -4bps to 90.69% in 2023, then dropped by -1bps to 89.57% in 2024, then dropped by -4bps to 85.84% in 2025.
  • Per Business Quant, the three most recent readings for RARE's Gross Margin are 85.84% (Q4 2025), 82.5% (Q3 2025), and 86.18% (Q2 2025).